CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees

Mosaic ImmunoEngineering Inc.

Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.
Amount owed to CWRU increased to approximately $407,000 as of Dec. 31, 2023; company lacks capital to pay.
Company evaluating strategic options including additional capital, M&A, or possible wind-down/liquidation.
License was for foundational technology (CPMV) behind MIE-101, the sole immunotherapy candidate.

item 1.01 item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Mosaic ImmunoEngineering Inc. terminated License Agreement with Case Western Reserve University (effective 2024-03-22).

Action: termination
Agreement: license
Counterparty: Case Western Reserve University
Effective: 2024-03-22

Exact text from the filing

on March 22, 2024, the Company received a letter of termination from CWRU terminating our Agreement effective immediately due to our financial default

View on SEC.gov

438 material agreements filed in the last 30 days. Browse all material agreements →

Mosaic ImmunoEngineering Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.